|Bid||56.040 x 400|
|Ask||56.050 x 400|
|Day's Range||55.770 - 56.180|
|52 Week Range||46.010 - 76.800|
|PE Ratio (TTM)||19.45|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||1.56 (2.80%)|
|1y Target Est||57.59|
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications.
Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ...
The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.